Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma

Fig. 1

Results of portal vein phase imaging with enhanced abdominal MRI and the changes in tumors in a representative case before TACE and at 1, 3 months after treatment in both two groups. MRI with tumor enhancement pre-TACE in a patient later treated with TACE-apatinib (a), and TACE-alone (d). Note the enhanced integrity of the tumor in both A and D. MRI with tumor enhancement scan in the patient treated with TACE-apatinib (b and c) and TACE-alone (e and f) at 1 and 3 months after treatment. Partial enhancement can be seen in Fig. b, c, e and f, and the strengthening part are obviously smaller than that of Figure a and d

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us